Drug Profile
Research programme: anthrax vaccine - Baxter Healthcare
Latest Information Update: 01 Apr 2011
Price :
$50
*
At a glance
- Originator Baxter International
- Developer Roche
- Class Anthrax vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anthrax
Most Recent Events
- 26 Jun 2007 BioVeris Corporation has been acquired and merged into Roche